ArticleNature communications2022
A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 53 citations in OpenAlex.
- Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial.EBioMedicine · 2025Trial
- TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study.Nature communications · 2025Trial
- Dendritic cell circadian clocks shape memory CD8Science advances · 2026Article
- Non-cytolytic re-engineering of a viral vaccine vector enables durable effector-memory T cell immunity by reinforcing type I IFN induction.Molecular therapy. Nucleic acids · 2026Article
- Design of antibody structure-guided epitope vaccinesJournal of virology · 2025Article
- Conserved CD8 T cell vaccines without B cell epitopes drive robust protection against SARS-CoV-2 that is enhanced by intranasal boost.Science advances · 2025Article
- Bivalent mRNA vaccine booster enhances immunity against XBB.1.5 more effectively than breakthrough infection in K18-hACE2 mice.iScience · 2025Article
- Article
- The Impact of Vaccination Frequency on COVID-19 Public Health Outcomes: A Model-Based Analysis.Vaccines · 2025Article
- Developing T Cell Epitope-Based Vaccines Against Infection: Challenging but Worthwhile.Vaccines · 2025Review
- Patterns of restricted TCR usage following SARS-CoV-2 vaccination and severe disease.Frontiers in immunology · 2025Article
- Characterizing HLA-A2-restricted CD8Frontiers in immunology · 2025Article
- Staggered immunization with mRNA vaccines encoding SARS-CoV-2 polymerase or spike antigens broadens the T cell epitope repertoire.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Design, Development and Immunogenicity Study of a Multi-Epitope Vaccine Prototype Against SARS-CoV-2.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Broad protection and respiratory immunity of dual mRNA vaccination against SARS-CoV-2 variants.NPJ vaccines · 2024Article
- mRNA-LNP vaccine-induced CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- A T cell-based SARS-CoV-2 spike protein vaccine provides protection without antibodies.JCI insight · 2024Article
- Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- SARS-CoV-2 immunity in animal models.Cellular & molecular immunology · 2024Review
- Multiantigen pan-sarbecovirus DNA vaccines generate protective T cell immune responses.JCI insight · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 4 institutions in 2 countries.
Iris N PardieckDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-1642-1857
Tetje C van der Sluis *Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-1804-1647
Esmé T I van der Gracht *Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-8329-7916
Dominique M B VeerkampDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-2761-1015
Felix M BehrDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-1158-5011
Suzanne van DuikerenDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-7391-5832
Guillaume BeyrendDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-9044-3486
Jasper RipDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-5780-9271
Reza NadafiDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
Elham Beyranvand NejadDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-9801-1351
Nils MüllingDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-3534-233X
Dena J BrasemDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
Marcel G M CampsDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
Sebenzile K MyeniDepartment of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-5813-0065
Peter J BredenbeekDepartment of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
Marjolein KikkertDepartment of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-5779-7386
Yeonsu KimDepartment of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Luka Cicin-SainDepartment of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.ORCID 0000-0003-3978-778X
Tamim AbdelaalDelft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands.ORCID 0000-0003-2719-5736
Klaas P J M van GisbergenDepartment of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands.ORCID 0000-0003-3623-7555
Kees L M C FrankenDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
Jan Wouter DrijfhoutDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-4808-5296
Cornelis J M MeliefISA Pharmaceuticals BV, Leiden, The Netherlands.
Gerben C M ZondagImmunetune BV, Leiden, The Netherlands.
Ferry OssendorpDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
Ramon ArensDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands. R.Arens@lumc.nl.ORCID 0000-0001-5058-4110
Leiden University Medical Center · NLHelmholtz Centre for Infection Research · DEISA Pharmaceuticals (Netherlands) · NLSanquin · NL
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding the mechanisms and impact of booster vaccinations are essential in the design and delivery of vaccination programs. Here we show that a three dose regimen of a synthetic peptide vaccine elicits an accruing CD8
Indexed as
COVID-19Epitopes, T-LymphocyteAnimalsAntibodies, NeutralizingAntibodies, ViralCD8-Positive T-LymphocytesDisease Models, AnimalImmunologic MemoryMiceSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationVaccines, SyntheticAntibodies, NeutralizingAntibodies, ViralEpitopes, T-LymphocyteSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, Synthetic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.